Sponsored by Endo Pharmaceuticals
This activity is not certified for credit.
Tuesday, September 6
This program will discuss the current and emerging role of buprenorphine in the treatment of chronic pain. Following a brief discussion of the biochemical pharmacology of full and partial agonists, faculty will present results from studies supporting the recent approval of BELBUCA™, the first oral buccal formulation of buprenorphine for chronic pain. The program will feature a panel discussion on the efficacy, safety, and tolerability of BELBUCA™ in both opioid-naïve and opioid-experienced patients.
No Preregistration Required
Jeffrey Fudin, BS, PharmD, FCCP
Jeffrey A. Gudin, MD
Richard Rauck, MD
Posted on August 13, 2016